The National Institutes of Health stopped the trial after an independent safety board concluded that the drug was unlikely to benefit patients.
Published: June 20, 2020 at 08:21PM
from NYT Health https://ift.tt/2zPBMVh
The National Institutes of Health stopped the trial after an independent safety board concluded that the drug was unlikely to benefit patients.
Published: June 20, 2020 at 08:21PM
from NYT Health https://ift.tt/2zPBMVh
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Google reCAPTCHA helps protect websites from spam and abuse by verifying user interactions through challenges.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com (opens in a new window)